MBOT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MBOT is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some promising commercial and international expansion catalysts, and sentiment in options is very bullish, but the technical setup is only moderately constructive and the company still lacks enough financial detail here to support a confident long-term buy decision. Since the user is impatient and does not want to wait for an ideal entry, my direct view is to hold rather than buy now.
MBOT is trading at 1.89 after a slight decline from 1.91. The MACD histogram is positive and expanding, which supports short-term momentum, while RSI at 62.231 is mildly bullish but not overbought. Moving averages are converging, suggesting a possible trend inflection rather than a fully established uptrend. Price is sitting just above pivot support at 1.881, with resistance at 1.99 and 2.057, so upside exists but the chart is not yet strong enough to call it an immediate high-conviction buy.
["Lucid Capital initiated coverage with a Buy rating and a $4 price target, well above the current price.", "The company has partnered with Sanmina to expand production capacity for the LIBERTY system, which may improve efficiency and lower costs.", "Recent clearance in Israel and efforts to obtain CE Mark support international expansion.", "The company is entering the commercial phase, which is a meaningful growth inflection.", "Bullish options sentiment suggests traders expect upside continuation."]
["Hedge funds are neutral and show no significant buying trend.", "Insiders are neutral with no meaningful recent accumulation.", "The stock has no strong AI Stock Picker or SwingMax signal today.", "Financial snapshot data is unavailable, limiting confidence in the long-term fundamentals.", "The chart still shows only a tentative trend with converging moving averages rather than a strong breakout."]
Latest quarter financial data was not provided due to an error in the financial snapshot, so a full fundamental review is limited. What can be inferred is that the company is moving into the commercial stage, which is usually a key early growth phase. However, without revenue, margin, and cash burn data for the latest quarter and season, it is not possible to confirm strong financial momentum.
Analyst sentiment is positive and improving. On 2026-06-03, Lucid Capital initiated coverage on Microbot Medical with a Buy rating and a $4 price target, arguing the Liberty robot is a novel product in a largely untapped category and that the market has not yet appreciated the commercial inflection. This is a bullish Wall Street view, but the broader hedge fund and insider picture remains neutral.
